Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem asparagine enzymes Coverage Update | OpenPa…
    Ask Trek AI about this page
    ModifiedAnthemPolicy CC-0096

    Asparagine Specific Enzymes (Erwinaze, Rylaze, Oncaspar, Asparlas) Coverage Criteria

    Customize your policy alerts

    Sign up for Anthem Policy CC-0096 alerts

    Get alerted when Policy CC-0096 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage criteria for asparagine specific enzymes (Erwinaze, Rylaze, Oncaspar, Asparlas) for treatment of acute lymphoblastic leukemia and select NK/T-cell lymphomas; applies to Anthem medical benefit reviews and prior authorization for covered members.

    Policy Summary
    PayerAnthem
    PolicyClinical/Medical Policy — Coverage Criteria for asparagine specific enzymes
    Policy CodePolicy CC-0096
    Change TypeMaterial revisions: added silent inactivation usemoved contraindications to 'may not be approved'HCPCS coding updates
    Effective DateMar 26, 2026
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of diagnosis and, when applicable, asparaginase activity testing to demonstrate silent inactivation (e.g., day 7 <0.1 IU/mL or day 14 <LLQ).
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Removed contraindications from criteria and moved them to 'may not be approved' (may not be approved criteria).

    Removed HCPCS J9019 and J9020 from coding effective 1/1/26.

    Added use in silent inactivation for Erwinaze and Rylaze criteria.

    Removed contraindications from criteria and moved them to 'may not be approved' criteria.

    Removed HCPCS J9019 and J9020 effective 1/1/26.

    Added use in silent inactivation for asparaginase enzyme (Erwinaze and Rylaze) criteria.

    4asparaginase products
    ≤21 yrsage range (Asparlas)
    day7 <0.1 IU/mLsilent inactivation threshold
    2ANCCN recommendation
    NCCN citedNCCN cited

    Coverage Criteria for Asparagine-Specific Enzymes

    Erwinaze / Rylaze approval criteria

    Erwinaze or Rylaze may be approved when ALL of the following are met:

    Age or diagnosis: Individual is under 19 years of age OR individual has a diagnosis of acute lymphoblastic lymphoma or acute lymphocytic (lymphoblastic) leukemia (ALL) OR extranodal Natural Killer T‑cell lymphoma (ENKL)

    ENKL per NCCN 2A

    Hypersensitivity or silent inactivation: Individual has developed a documented systemic allergic reaction or anaphylaxis to prior E. coli–derived asparaginase OR has silent inactivation defined as day 7 asparaginase activity < 0.1 IU/mL and/or day 14 asparaginase activity below the lower limit of quantification (LLQ)day 7 < 0.1 IU/mL or day 14 < LLQ

    Silent inactivation preferably confirmed in two independent samples

    Oncaspar approval criteria

    Oncaspar may be approved when ALL of the following are met:

    Age or diagnosis: Individual is under 19 years of age OR individual has a diagnosis of acute lymphoblastic lymphoma or acute lymphocytic (lymphoblastic) leukemia (ALL) OR extranodal Natural Killer T‑cell lymphoma (ENKL)

    ENKL per NCCN 2A; Drugdex cited

    Asparlas approval criteria

    Asparlas may be approved when ALL of the following are met:

    Age and diagnosis: Individual is under 19 years of age OR individual is 19 to 21 years of age AND individual has a diagnosis of acute lymphoblastic lymphoma or acute lymphocytic (lymphoblastic) leukemia (ALL)

    Asparlas label and NCCN 2A support use through age 21

    Criteria updates and context

    Criteria updates, document history, and guidance context:

    Updates summary: Criteria were updated to add use in silent inactivation for Erwinaze and Rylaze; contraindications were removed from the main approval criteria and relocated to 'may not be approved' criteria; Oncaspar criteria were revised (NCCN recommendation for hepatosplenic T‑cell lymphoma removed).

    See referenced NCCN guidance and expert recommendations in References

    Requests may be may not be approved when the individual has a documented history of serious adverse events related to prior L‑asparaginase therapy, including: a history of serious thrombosis, a history of serious pancreatitis, or a history of serious hemorrhagic events. These conditions are listed as exclusionary for Erwinaze/Rylaze, Oncaspar, and Asparlas when present with prior L‑asparaginase exposure and, for Oncaspar and Asparlas, severe hepatic impairment is an additional condition that may preclude approval.

    Operationally, contraindications previously embedded in the main agent criteria were removed during the 02/20/2026 annual review and reclassified under the policy’s may not be approved section. This change centralizes exclusion conditions and clarifies that those situations are managed as denial triggers rather than as part of the positive approval logic.

    For clarity in policy structure, conditions that had been labeled as contraindications in earlier versions are now located in the operational may not be approved area of the coverage criteria. See the document history (02/20/2026) for the formal change; the specific agent sections continue to list the same clinical events (e.g., serious thrombosis, pancreatitis, hemorrhagic events, and for some agents severe hepatic impairment) as reasons that a request may not be approved.

    Coding: HCPCS and Diagnosis Codes

    HCPCS (selected agents)HCPCS
    J9021Injection, asparaginase, recombinant, (Rylaze), 0.1 mg
    J9266Injection, pegaspargase, per single dose vial [Oncaspar]
    HCPCS (Asparlas)HCPCS
    J9118Injection, calaspargase pegol-mknl, 10 units [Asparlas]
    ICD-10 Diagnosis codesICD-10
    C83.50-C83.59Lymphoblastic (diffuse) lymphoma
    C84.Z0-C84.Z9Other mature T/NK-cell lymphomas
    C84.90-C84.99Mature T/NK-cell lymphomas, unspecified
    C86.00Extranodal NK/T-cell lymphoma, nasal type not having achieved remission
    C91.00-C91.02Acute lymphoblastic leukemia (ALL)
    Diagnosis and HCPCS coding mentionedmixed
    C83.50-C83.59Lymphoblastic (diffuse) lymphoma
    C91.00-C91.02Acute lymphoblastic leukemia (ALL) / Lymphoblastic (diffuse) lymphoma
    J9021HCPCS code added for Rylaze
    J9118HCPCS code for Asparlas
    J9019HCPCS code removed effective 1/1/26
    J9020HCPCS code removed effective 1/1/26
    Asparaginase activity threshold for silent inactivation
    Day 7 activity thresholdAsparaginase trough activity < 0.1 IU/mL on day 7
    Day 14 activity thresholdAsparaginase trough activity below the assay lower limit of quantification (LLQ) on day 14
    Confirmation recommendationPreferably confirmed in two independent samples to reduce false positives
    N/A
    N/ANo additional coding key-value content
    PlaceholderNo action required

    Provider Actions, Prior Authorization, and Documentation Requirements

    Prior Authorization

    Agent-specific prior authorization

    Prior authorization is required for Erwinaze (asparaginase [erwinia chrysanthemi]) and Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) and is conditioned on age, diagnosis, and supporting documentation of allergy or silent inactivation. Requests will be reviewed against the clinical criteria (e.g., age <19 and diagnosis of ALL/related ICD-10 codes) and may be denied if criteria are not met.

    • Prior authorization required and clinical review applies to medical benefit drug requests.
    • Approval contingent on meeting age, diagnosis, and documentation criteria per policy.
    Step Therapy

    Therapy sequencing note

    Erwinaze/Rylaze are positioned for patients who cannot receive or have failed E. coli–derived asparaginase products (Oncaspar/Asparlas) due to documented systemic allergic reaction/anaphylaxis or silent inactivation. Sequencing should reflect the label and NCCN-based indications; document why switching to an Erwinia-derived product is clinically necessary.

    Background and Rationale

    Asparagine‑specific enzymes (asparaginase products) work by depleting circulating asparagine, exploiting the inability of some leukemic and lymphomatous cells to synthesize asparagine de novo; deprivation of this amino acid leads to leukemic cell death. These agents include E. coli–derived pegylated formulations and Erwinia‑derived formulations used in acute lymphoblastic leukemia (ALL) and selected NK/T‑cell lymphomas. Clinically, asparaginase is used both as a component of first‑line multi‑agent regimens (pegylated forms) and as a replacement option when patients develop hypersensitivity or silent inactivation to E. coli–derived products; silent inactivation is identified by low trough asparaginase activity and reflects neutralizing anti‑asparaginase antibodies that reduce drug activity without overt allergic symptoms.

    Definitions and Key Terms

    Acute leukemia
    DefinitionAcute leukemia: A rapidly developing leukemia where abnormal leukemic cells do not perform the normal functions of white blood cells.
    Clinical contextIncludes leukemias that progress quickly and require prompt treatment decisions
    Related termsMay be specified as lymphoid, lymphoblastic, or lymphocytic leukemia when arising from lymphoid cells
    Silent inactivation
    Core definitionSilent inactivation: Neutralizing anti-asparaginase (or anti-PEG) antibodies cause asparaginase inactivity without clinical hypersensitivity symptoms.
    IdentificationDetected by trough asparaginase activity levels below the assay lower limit of quantification (LLQ) in patients without clinical allergy

    Line of Therapy Positioning

    first-line

    First‑line use context:

    First‑line component: Oncaspar and Asparlas are indicated/approved as components of multi‑agent first‑line chemotherapy regimens for acute lymphoblastic leukemia (ALL) per product labeling; Asparlas is approved for patients 1 month to 21 years of age.

    See product labels and NCCN guidance

    salvage

    Salvage / replacement therapy context:

    Hypersensitivity management: Erwinaze and Rylaze are positioned for patients who develop hypersensitivity (systemic allergic reaction or anaphylaxis) or silent inactivation to E. coli–derived asparaginase and are used as replacement therapy in that setting.

    Silent inactivation defined by asparaginase activity thresholds

    first-line (alternate)

    Biomarker and Laboratory Requirements

    Asparaginase activity — required lab thresholds
    Day 7 thresholdDocumented asparaginase activity < 0.1 IU/mL on day 7
    Day 14 thresholdDocumented asparaginase activity below the lower limit of quantification (LLQ) on day 14
    PurposeRequired laboratory evidence to document silent inactivation when considering Erwinaze or Rylaze as replacement therapy
    Confirmation recommendationPreferably confirmed in two independent samples to reduce false positive identification

    Preferred Regimens and Agent Use

    Regimen / ContextNCCN recommendationCoverage stance
    Pegaspargase-based regimens for extranodal NK/T‑cell lymphoma, nasal type (ENKL)NCCN: category 2A — pegaspargase-based regimens preferredPreferred (covered with criteria)
    AgentPermitted uses / place in therapyRelevant criteria or labeling notesCoverage stance
    Oncaspar (pegaspargase)Component of multi‑agent first‑line chemotherapy for ALL; use in ENKL noted by NCCN (pegaspargase‑based regimens preferred)Approved per label for first‑line use in eligible patients; NCCN 2A supports pegaspargase regimens in ENKLCovered with criteria (age/diagnosis requirements)
    Erwinaze (asparaginase, Erwinia chrysanthemi)Used as replacement therapy for patients with documented systemic allergic reaction/anaphylaxis to E. coli‑derived asparaginase or for silent inactivationCriteria allow use when patient has hypersensitivity or silent inactivation (day 7 activity <0.1 IU/mL and/or day 14 Covered with criteria (replacement therapy for hypersensitivity or silent inactivation)
    Rylaze (recombinant asparaginase)Positioned as replacement for E. coli‑derived asparaginase in patients with hypersensitivity or silent inactivation; added to criteria and coding in document historyUse permitted for documented systemic allergic reaction or silent inactivation (asparaginase activity thresholds apply) per criteria; HCPCS J9021 applicableCovered with criteria (replacement therapy for hypersensitivity or silent inactivation)
    Asparlas (calaspargase pegol‑mknl)Indicated/approved as component of first‑line multi‑agent chemotherapy for ALL; NCCN notes Asparlas may be substituted for pegaspargase in patients ≤21 years for more sustained activityLabel and NCCN support use in patients ≤21 years as an alternative to pegaspargase; separated from other agents in coding updatesCovered with criteria (age/diagnosis requirements)

    Document History and Changes

    2026-02-20Annual Review (material)Latest

    Removed contraindications from the main coverage criteria and relocated them to 'may not be approved' criteria; coding reviewed with no changes.

    2025-11-21Coding Update

    Removed HCPCS codes J9019 and J9020 effective 2026-01-01.

    2025-08-15Select Review (material)
    Policy Summary
    PayerAnthem
    PolicyClinical/Medical Policy — Coverage Criteria for asparagine specific enzymes
    Policy CodePolicy CC-0096
    Change TypeMaterial revisions: added silent inactivation usemoved contraindications to 'may not be approved'HCPCS coding updates
    Effective DateMar 26, 2026
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of diagnosis and, when applicable, asparaginase activity testing to demonstrate silent inactivation (e.g., day 7 <0.1 IU/mL or day 14 <LLQ).
    SourceLink
    On This Page
    Coverage Criteria for Asparagine-Specific EnzymesCoding: HCPCS and Diagnosis CodesProvider Actions, Prior Authorization, and Documentation RequirementsBackground and RationaleDefinitions and Key TermsLine of Therapy PositioningBiomarker and Laboratory RequirementsPreferred Regimens and Agent UseDocument History and Changes
    Inventory noteRetained for structural completeness only
    • Use Erwinaze/Rylaze when patient has hypersensitivity or silent inactivation to E. coli–derived asparaginase (e.g., pegaspargase).
    • Oncaspar and Asparlas remain first-line where not contraindicated; Erwinaze/Rylaze are alternatives when allergies or inactivation occur.
    Documentation Required

    Silent inactivation laboratory documentation

    Documented laboratory evidence of silent inactivation is required when approval is based on suspected silent inactivation. Provide trough asparaginase activity results demonstrating inactivation (preferably two independent samples). Specifically, for pegaspargase regimens: a day 7 asparaginase activity <0.1 IU/mL and/or a day 14 level below the laboratory's lower limit of quantification (LLQ) supports silent inactivation.

    • Preferred confirmation: two independent trough activity measurements to minimize false positives.
    • Accepted thresholds: day 7 <0.1 IU/mL and/or day 14 < LLQ (per van der Sluis et al.).
    Documentation Required

    Required clinical documentation

    Providers must supply clinical documentation supporting the requested agent, including diagnosis codes and clinical rationale aligned with NCCN guidance. Include the member's diagnosis (ICD-10 ranges used in the policy such as ALL and related lymphomas), prior asparaginase agent(s) administered, details of any systemic allergic reactions or anaphylaxis, and prior therapy toxicities or contraindications that justify switching agents.

    • Include relevant ICD-10 diagnosis codes (policy-added ranges for ALL/lymphomas).
    • Document prior E. coli–derived asparaginase exposure and timing.
    • If denying prior therapy was due to thrombosis, pancreatitis, or hemorrhagic events, provide clinical notes and imaging/lab evidence.
    Denial Risk

    Common denial triggers and coding consistency

    Common denial triggers include absence of documented allergy or laboratory-confirmed silent inactivation, history of serious thrombosis, pancreatitis, or hemorrhagic events with prior L-asparaginase therapy, or requests with inconsistent coding or references to removed HCPCS codes. Ensure clinical rationale and coding are consistent with the current HCPCS list and document rationale when deviating from first-line agents.

    • Denial risks: no documented systemic allergic reaction or no lab evidence of silent inactivation.
    • Denial risks: prior serious thrombosis, pancreatitis, or hemorrhagic events with L-asparaginase therapy.
    • Denial risks: use of removed HCPCS codes (e.g., J9019/J9020 removed effective 1/1/26) or inconsistent product coding.
    Measurement notePreferably measured in two independent samples to minimize false positives
    Silent inactivation (alternate entry)
    Alternate termsilent inactivation (lowercase entry identical in meaning)
    MechanismCaused by neutralizing anti-drug antibodies to asparaginase or PEG leading to loss of circulating enzyme activity
    Clinical implicationMay occur without overt allergic reaction; requires laboratory confirmation for therapy change decisions

    Additional first‑line guidance context:

    Guideline referenced: NCCN Clinical Practice Guidelines (ALL, Pediatric ALL, T‑Cell Lymphomas) are cited to support place‑in‑therapy determinations and preferred regimens (e.g., NCCN 2A recommendation for pegaspargase‑based regimens in ENKL).

    See References for guideline versions

    Added use for silent inactivation to Erwinaze and Rylaze criteria and updated ICD-10 coding (added C86.00); separated Asparlas from other agents in coding review.

    2025-02-21Annual Review

    No clinical changes to criteria; coding reviewed with additions of applicable agents to diagnosis descriptions (Erwinaze, Rylaze, Oncaspar, Asparlas added to several ICD-10 ranges).

    2024-08-16Annual Review

    Reintroduced Erwinaze to the criteria document; coding reviewed with addition of ICD-10-CM ranges C84.90-C84.Z0 and removal of C86.1 effective 2024-02-23.

    2024-02-23Annual Review

    Removed Erwinaze from the document (no longer available) earlier in the year; added NCCN 2A use in ENKL for Rylaze and updated Oncaspar criteria to remove an NCCN recommendation for hepatosplenic T-cell lymphoma.